Joseph Shulman - Feb 11, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Technical Officer
Signature
/s/ Hunter Smith, attorney-in-fact for Joseph Shulman
Stock symbol
RYTM
Transactions as of
Feb 11, 2023
Transactions value $
-$14,886
Form type
4
Date filed
2/14/2023, 08:00 PM
Previous filing
Feb 14, 2023
Next filing
Nov 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +1.56K +57.21% 4.3K Feb 11, 2023 Direct F1
transaction RYTM Common Stock Sale -$14.9K -554 -12.9% $26.87 3.74K Feb 14, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -1.56K -33.35% $0.00 3.12K Feb 11, 2023 Common Stock 1.56K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date.